Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.51 |
| ▸ | ITGAL | P20701 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | GRN | P28799 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561849 | 1.00 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| Hydrochloric Acid SCHEMBL4862500 | 0.99 | ALDH1A1 (0.57) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL30051464 | 0.91 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL6976264 | 0.91 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL9272265 | 0.91 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL7357698 | 0.91 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL8667829 | 0.90 | ALDH1A1 (0.56) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL9230708 | 0.89 | KDM4C (0.59) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL4891798 | 0.84 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL7339828 | 0.83 | GRN (0.70) | ALDH1A1MAPTRAB9ASMN1; SMN2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| CN-1282736-A | Method of preparing medicinal active substance derived from quinogold | HOFFMANN LA ROCHE (CH) | 2001-02-07 | — | — | CN | disclosed |
| CN-1054598-C | Pharmacologically active hydrazine derivatives and processes for preparation thereof | NORVATIS CO (CH) | 2000-07-19 | — | — | CN | disclosed |
| US-5914404-A | Process for the preparation of quinargine | HOFFMANN-LA ROCHE INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| CN-1173494-A | Preparation method of quinolin | HOFFMANN LA ROCHE (CH) | 1998-02-18 | — | — | CN | disclosed |
| EP-0812839-A1 | Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof | LG Chemical Limited (KR) | 1997-12-17 | — | — | EP | disclosed |
| US-5696134-A | Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof | LG CHEMICAL LIMITED (KR) | 1997-12-09 | — | — | US | disclosed |
| US-5670517-A | MULTISTAGE SYNTHESIS WITH EPOXIDATION, DECARBONYLATION, COUPLING BY AMIDATION THEN DECARBONYLATION | LG CHEMICAL LIMITED (KR) | 1997-09-23 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0687675-A2 | Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof | LG Chemical Limited (KR) | 1995-12-20 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| US-5296604-A | Proline derivatives and compositions for their use as inhibitors of HIV protease | MILES INC. (US) | 1994-03-22 | — | — | US | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | ALDH1A1 889/4885GAA 27/4885MAPT 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.